Celltrion Healthcare’s high-concentration adalimumab biosimilar demonstrated comparable safety, efficacy, and immunogenicity profiles to the reference product for up to a year, providing further evidence supporting use of the product. Celltrion Healthcare sha..

Introduction Glaucoma is a chronic disorder that requires long-term treatment. In common with other insidious diseases such as hypertension or type-2 diabetes, obtaining patient compliance and long-term adherence with treatment is a key factor in achieving a g..

MARINAVLADIVOSTOK / WIKIMEDIA COMMONS Micafungin is as effective at preventing fungal infections in leukaemia patients but is better tolerated than older formulations of posaconazole, interim results from a study suggested. The research, presented at the ..

Some patients treated with a bimatoprost slow-release implant over 1 year can maintain the IOP-lowering effect without relapse for 2 years or even 4 years after the last administration, according to a study.“We believe that upregulation of the metalloproteina..

The European Commission has approved atezolizumab for use as a frontline treatment in patients with metastatic non–small cell lung cancer whose tumors have a high PD-L1 expression and do not harbor EGFR or ALK aberrations.The European Commission has approved ..

The combination of alpelisib and fulvestrant maintained a tolerable safety profile for patients with PIK3CA-mutated, hormone receptor–positive, HER2-negative advanced breast cancer who progressed after previous treatment with a CDK4/6 inhibitor. Alpelisib (Pi..

In a recent development , the noninferiority of 25-μg misoprostol every four hours to the dinoprostone pessary for cesarean delivery (CD) rates after induction of labour (IOL) at term could not be demonstrated, although results from the study highlighted that..

Background: Rituximab provides more effective and less adverse effects than the standard dose of corticosteroids, but evidence on its efficacy and safety in the Thai population is lacking.Objective: To evaluate the efficacy and safety of rituximab in the t..

Karen L. Reckamp, th progression-free survival benefit achieved with ramucirumab in patients with EGFR-positive lung cancer. During a virtual Targeted Oncology Case-Based Roundtable event, Karen L. Reckamp, MD, MS, director, Division of Medical Oncology,..